<?xml version="1.0" encoding="ISO-8859-1"?>
<rss version= "2.0">
<channel>
<title>Latest Drug  News</title>
<link>http://www.medindia.net/health-press-release/Drug-News.asp</link>
<description>Medindia largest health website in india.</description>
<language>en-us</language>
<copyright>Copyright 2012. All Rights Reserved.</copyright>
<lastBuildDate>Sat, 26 May 2012 08:38:17 GMT</lastBuildDate>
<item>
<title><![CDATA[Albemarle to increase ibuprofen prices]]></title>
 <link>http://www.medindia.net/health-press-release/Albemarle-to-increase-ibuprofen-prices-140055-1.htm</link>
 <description><![CDATA[
	BATON ROUGE, La., May 25, 2012 /PRNewswire/ --Albemarle Corporation (NYSE: ALB), a global developer, manufacturer and marketer of highly engineered specialty chemicals, announced today that it will increase global prices for all grades of ibuprofen by an estimated 15% effective immediately, or as contracts allow.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Albemarle-to-increase-ibuprofen-prices-140055-1.htm</guid>
</item>
<item>
<title><![CDATA[NORD Calls Senate Bill Most Important Since Orphan Drug Act]]></title>
 <link>http://www.medindia.net/health-press-release/NORD-Calls-Senate-Bill-Most-Important-Since-Orphan-Drug-Act-139985-1.htm</link>
 <description><![CDATA[
	Praises Senate for Addressing Needs of Rare Disease Patients
	WASHINGTON, May 24, 2012 /PRNewswire-USNewswire/ --The National Organization for Rare Disorders (NORD) applauds legislation passed today by the U.S. Senate -- S 3187, the Food and Drug Administration Safety  (and)  Innovation Act of ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/NORD-Calls-Senate-Bill-Most-Important-Since-Orphan-Drug-Act-139985-1.htm</guid>
</item>
<item>
<title><![CDATA[Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal]]></title>
 <link>http://www.medindia.net/health-press-release/Valeant-Pharmaceuticals-Agrees-to-Acquire-Certain-Assets-from-Swiss-Herbal-139887-1.htm</link>
 <description><![CDATA[
	MONTREAL, Quebec, May 24, 2012 /PRNewswire/ --Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has agreed to acquire certain assets from Swiss Herbal Remedies Limited, a nutraceutical company that manufactures and markets a broad range of scientifically formulated vitamins, ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Valeant-Pharmaceuticals-Agrees-to-Acquire-Certain-Assets-from-Swiss-Herbal-139887-1.htm</guid>
</item>
<item>
<title><![CDATA[Polio eradication shifts into emergency mode]]></title>
 <link>http://www.medindia.net/health-press-release/Polio-eradication-shifts-into-emergency-mode-139870-1.htm</link>
 <description><![CDATA[
	New cases at lowest levels ever, but funding gap threatens progress
	GENEVA, May 24,2012 /PRNewswire-USNewswire/ --Despite the dramatic drop in polio cases in the last year, the threat of continued transmission due to funding and immunization gaps has driven the Global Polio Eradication Initiative (GPEI) to launch an Emergency Action Plan.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Polio-eradication-shifts-into-emergency-mode-139870-1.htm</guid>
</item>
<item>
<title><![CDATA[FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO (Regd)  to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome]]></title>
 <link>http://www.medindia.net/health-press-release/FDA-Advisory-Committee-Recommends-Against-Approval-of-Oral-Anticoagulant-XARELTO-to-Reduce-the-Risk-of-Secondary-Cardiovascular-Events-in--139838-1.htm</link>
 <description><![CDATA[
	RARITAN, N.J., May 23, 2012 /PRNewswire/ -- Janssen Research  (and)  Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has votedagainst the approval of XARELTO (Regd)  (rivaroxaban), an oral anticoagulant, to reduce the risk ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/FDA-Advisory-Committee-Recommends-Against-Approval-of-Oral-Anticoagulant-XARELTO-to-Reduce-the-Risk-of-Secondary-Cardiovascular-Events-in--139838-1.htm</guid>
</item>
<item>
<title><![CDATA[Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs]]></title>
 <link>http://www.medindia.net/health-press-release/Drug-Price-Cuts-in-Top-Five-Countries-of-Europe-Tougher-Reference-Pricing-Environment-and-Drug-Price-Freeze-through-2013--139714-1.htm</link>
 <description><![CDATA[
	NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
	a href="http:www.reportlinker.com/p0866955/Drug-Price-Cuts-in-Top-Five-Countries-of-Europe---Tougher-Reference-Pricing-Environment-and-Drug-Price-Freeze-through-2013-Expected-to-Drive-Down-Healthcare-Costs.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Drug-Price-Cuts-in-Top-Five-Countries-of-Europe-Tougher-Reference-Pricing-Environment-and-Drug-Price-Freeze-through-2013--139714-1.htm</guid>
</item>
<item>
<title><![CDATA[TriReme Medical, Inc. Receives FDA Approval for Glider PTCA Catheter]]></title>
 <link>http://www.medindia.net/health-press-release/TriReme-Medical-Inc-Receives-FDA-Approval-for-Glider-PTCA-Catheter-139713-1.htm</link>
 <description><![CDATA[
	PLEASANTON, Calif., May 23, 2012 /PRNewswire/ -- TriReme Medical, Inc. (TMI) today announced approval by the U.S. Food and Drug Administration (FDA) of the Glider PTCA Catheter, indicated for treating the stenotic portion of coronary arteries or bypass grafts to improve myocardial perfusion.
	Glider is the world's only torqueable PTCA balloon catheter.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/TriReme-Medical-Inc-Receives-FDA-Approval-for-Glider-PTCA-Catheter-139713-1.htm</guid>
</item>
<item>
<title><![CDATA[Veloxis Pharmaceuticals announces a restructuring of the company to support and strengthen strategic focus on LCP-Tacro and announces changes to management]]></title>
 <link>http://www.medindia.net/health-press-release/Veloxis-Pharmaceuticals-announces-a-restructuring-of-the-company-to-support-and-strengthen-strategic-focus-on-LCP-Tacro-and-announces--139711-1.htm</link>
 <description><![CDATA[
	
			
				span style="FONT-FAMILY: ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Veloxis-Pharmaceuticals-announces-a-restructuring-of-the-company-to-support-and-strengthen-strategic-focus-on-LCP-Tacro-and-announces--139711-1.htm</guid>
</item>
<item>
<title><![CDATA[Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs]]></title>
 <link>http://www.medindia.net/health-press-release/Pricing-and-Reimbursement-in-Brazil-Health-Technology-Assessment-HTA-Studies-to-Facilitate-Setting-of-Ceiling-Prices-for-New-Drugs--139708-1.htm</link>
 <description><![CDATA[
	NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
	a href="http:www.reportlinker.com/p0866956/Pricing-and-Reimbursement-in-Brazil---Health-Technology-Assessment-(HTA)-Studies-to-Facilitate-Setting-of-Ceiling-Prices-for-New-Drugs.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Pricing-and-Reimbursement-in-Brazil-Health-Technology-Assessment-HTA-Studies-to-Facilitate-Setting-of-Ceiling-Prices-for-New-Drugs--139708-1.htm</guid>
</item>
<item>
<title><![CDATA[Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential]]></title>
 <link>http://www.medindia.net/health-press-release/Antibacterials-Market-to-2017-Innovative-Anti-Infectives-that-Target-MDR-Gram-Negative-Pathogens-Offer-Significant-Revenue-Potential-139706-1.htm</link>
 <description><![CDATA[
	NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
	a href="http:www.reportlinker.com/p0866959/Antibacterials-Market-to-2017---Innovative-Anti-Infectives-that-Target-MDR-Gram-Negative-Pathogens-Offer-Significant-Revenue-Potential.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Antibacterials-Market-to-2017-Innovative-Anti-Infectives-that-Target-MDR-Gram-Negative-Pathogens-Offer-Significant-Revenue-Potential-139706-1.htm</guid>
</item>
<item>
<title><![CDATA[MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent]]></title>
 <link>http://www.medindia.net/health-press-release/MicuRx-Pharmaceuticals-Announces-Issuance-Of-US-Patent-For-Its-Next-Generation-Antibacterial-Agent-139703-1.htm</link>
 <description><![CDATA[
	HAYWARD, Calif., and SHANGHAI, May 23, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/MicuRx-Pharmaceuticals-Announces-Issuance-Of-US-Patent-For-Its-Next-Generation-Antibacterial-Agent-139703-1.htm</guid>
</item>
<item>
<title><![CDATA[Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream]]></title>
 <link>http://www.medindia.net/health-press-release/Perrigo-Receives-FDA-Approval-for-Butoconazole-Nitrate-2-Vaginal-Cream-139690-1.htm</link>
 <description><![CDATA[
	ALLEGAN, Mich., May 22, 2012 /PRNewswire/ --Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for butoconazole nitrate 2% vaginal cream, the generic equivalent of Gynazole-1 (Regd) .Perrigo was the ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Perrigo-Receives-FDA-Approval-for-Butoconazole-Nitrate-2-Vaginal-Cream-139690-1.htm</guid>
</item>
<item>
<title><![CDATA[A Disturbing Picture of Increasing Epidemic Levels of Use of Dangerous Drugs has Been Revealed by the MixMag Survey Report, Published Today]]></title>
 <link>http://www.medindia.net/health-press-release/A-Disturbing-Picture-of-Increasing-Epidemic-Levels-of-Use-of-Dangerous-Drugs-has-Been-Revealed-by-the-MixMag-Survey--132777-1.htm</link>
 <description><![CDATA[
	LONDON, March 15, 2012 /PRNewswire/ --
	Amongst clubbers, Mephedrone use in the last year has risen by 20 percent and for Ketamine it is nearer 50 percent.
	The survey indicates a culture of young people using multiple drugs at a time fuelled by the emergence of new club drugs and 'legal highs'. Very little ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/A-Disturbing-Picture-of-Increasing-Epidemic-Levels-of-Use-of-Dangerous-Drugs-has-Been-Revealed-by-the-MixMag-Survey--132777-1.htm</guid>
</item>
<item>
<title><![CDATA[Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012]]></title>
 <link>http://www.medindia.net/health-press-release/Annual-Drug-Discovery-Conferences-Being-Held-in-Boston-MA-Spring-2012-132752-1.htm</link>
 <description><![CDATA[
	FARMINGTON, Conn., March 14, 2012
		/PRNewswire-iReach/ -- Global Information Inc. is excited to announce 4 significant Drug Discovery and Healthcare conferences scheduled for Boston, MA in the Spring of 2012. 
	8th ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Annual-Drug-Discovery-Conferences-Being-Held-in-Boston-MA-Spring-2012-132752-1.htm</guid>
</item>
<item>
<title><![CDATA[Saturday St. Patty's Day Doubles Drinking Violations]]></title>
 <link>http://www.medindia.net/health-press-release/Saturday-St-Pattys-Day-Doubles-Drinking-Violations-132735-1.htm</link>
 <description><![CDATA[New data shows added risks of weekend holiday
	DENVER, March 14, 2012 /PRNewswire/ --Newly released data on offenders monitored 24/7 for alcohol consumption shows that when St. Patrick's Day falls on a Saturday, drinking violations are more than double what they are for a mid-week holiday.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Saturday-St-Pattys-Day-Doubles-Drinking-Violations-132735-1.htm</guid>
</item>
<item>
<title><![CDATA[The Impact of Alcohol in our Communities]]></title>
 <link>http://www.medindia.net/health-press-release/The-Impact-of-Alcohol-in-our-Communities-132733-1.htm</link>
 <description><![CDATA[
	
	
	
	What: Forum on: The Impact of Alcohol in our Communities 
	(Logo: http:photos.prnewswire.com/prnh/20110727/DC41105LOGO )
	
	Who: 
	
		The Boyle Heights Stakeholders Association, 
		The Boyle Heights ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/The-Impact-of-Alcohol-in-our-Communities-132733-1.htm</guid>
</item>
<item>
<title><![CDATA[Collaborative Preclinical Efficacy Studies Suggest a New Target for Drug Addiction Treatment]]></title>
 <link>http://www.medindia.net/health-press-release/Collaborative-Preclinical-Efficacy-Studies-Suggest-a-New-Target-for-Drug-Addiction-Treatment-132728-1.htm</link>
 <description><![CDATA[
	
	MENLO PARK, Calif., March 14, 2012 /PRNewswire/ -- In preclinical studies,
		researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.
	This potential new drug target belongs to a ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Collaborative-Preclinical-Efficacy-Studies-Suggest-a-New-Target-for-Drug-Addiction-Treatment-132728-1.htm</guid>
</item>
<item>
<title><![CDATA[Cocaine Positives Spike 33% After New Government Rule for Safety-Sensitive Workers]]></title>
 <link>http://www.medindia.net/health-press-release/Cocaine-Positives-Spike-33-After-New-Government-Rule-for-Safety-Sensitive-Workers-132616-1.htm</link>
 <description><![CDATA[Amphetamines Positives Jump Nearly 26% After New Rule, Continuing Upward Trend, Shows Quest Diagnostics Drug Testing Index
	MADISON, N.J., March 13, 2012 /PRNewswire/ --Safety-sensitive workers have been subject to more stringent government drug testing rules over the past year, and the crackdown may be paying off, ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Cocaine-Positives-Spike-33-After-New-Government-Rule-for-Safety-Sensitive-Workers-132616-1.htm</guid>
</item>
<item>
<title><![CDATA[Medicine Dispensing Systems Provides Expert Assistance for the Preparation of Arizona Medical Marijuana Dispensary Applications]]></title>
 <link>http://www.medindia.net/health-press-release/Medicine-Dispensing-Systems-Provides-Expert-Assistance-for-the-Preparation-of-Arizona-Medical-Marijuana-Dispensary-Applications-132461-1.htm</link>
 <description><![CDATA[Thousands of Applications are Expected to be Submitted to the State
	
	
	
	
	HOLLYWOOD, Calif., March 12, 2012 /PRNewswire/ --Medicine Dispensing Systems, Inc. (MDS), a subsidiary of Medbox, Inc. (Pinksheets: MDBX) (www.medboxinc.com) is consulting ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Medicine-Dispensing-Systems-Provides-Expert-Assistance-for-the-Preparation-of-Arizona-Medical-Marijuana-Dispensary-Applications-132461-1.htm</guid>
</item>
<item>
<title><![CDATA[World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)]]></title>
 <link>http://www.medindia.net/health-press-release/World-Market-for-Prescription-Dermatological-Drugs-8th-Edition-Antiacne-Antiaging-Dermatitis-Hair-Loss-Psoriasis-Skin-Cancer-Melasma-and-Seborrhea--132421-1.htm</link>
 <description><![CDATA[
	NEW YORK, March 12, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
	a href="http:www.reportlinker.com/p0790441/World-Market-for-Prescription-Dermatological-Drugs-8th-Edition-(Antiacne-Antiaging-Dermatitis-Hair-Loss-Psoriasis-Skin-Cancer-Melasma-and-Seborrhea-Treatments).]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/World-Market-for-Prescription-Dermatological-Drugs-8th-Edition-Antiacne-Antiaging-Dermatitis-Hair-Loss-Psoriasis-Skin-Cancer-Melasma-and-Seborrhea--132421-1.htm</guid>
</item>
<item>
<title><![CDATA[Hovione Announces the Appointment of Colin Minchom, PhD, MRPharmS as Vice President, Particle Design Business Unit]]></title>
 <link>http://www.medindia.net/health-press-release/Hovione-Announces-the-Appointment-of-Colin-Minchom-PhD-MRPharmS-as-Vice-President-Particle-Design-Business-Unit-132420-1.htm</link>
 <description><![CDATA[
	LOURES, Portugal, March 12, 2012 /PRNewswire/ --
	Hovione today announced the appointment of Dr. Colin Minchom as Vice President of its Particle Design Business Unit. Dr. Minchom was most recently with Patheon where he held the position of Vice President, Pharmaceutical Development ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Hovione-Announces-the-Appointment-of-Colin-Minchom-PhD-MRPharmS-as-Vice-President-Particle-Design-Business-Unit-132420-1.htm</guid>
</item>
<item>
<title><![CDATA[Medical Marijuana Laboratory BudGenius Announces Free Online Medication Menu for Dispensaries]]></title>
 <link>http://www.medindia.net/health-press-release/Medical-Marijuana-Laboratory-BudGenius-Announces-Free-Online-Medication-Menu-for-Dispensaries-132411-1.htm</link>
 <description><![CDATA[BudGenius' new "MenuGenius" application educates patients and reduces operational costs for medical marijuana caregivers
	LOS ANGELES, March 12, 2012 /PRNewswire/ -- BudGenius.com, an online medical marijuana laboratory system developed by BG Medical Technologies, Inc.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Medical-Marijuana-Laboratory-BudGenius-Announces-Free-Online-Medication-Menu-for-Dispensaries-132411-1.htm</guid>
</item>
<item>
<title><![CDATA[PointCross Life Sciences Announces DSIMS: Drug Safety Information Management Suite]]></title>
 <link>http://www.medindia.net/health-press-release/PointCross-Life-Sciences-Announces-DSIMS-Drug-Safety-Information-Management-Suite-132403-1.htm</link>
 <description><![CDATA[
	FOSTER CITY, Calif., March 12, 2012 /PRNewswire/ -- The FDA has announced its intention to require Pharma companies to include nonclinical study data in standardized electronic formats as part of regulatory IND, NDA and BLA submissions. This directive is intended to help FDA reviewers better predict safety impacts of drugs in humans, and to improve regulatory science.]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/PointCross-Life-Sciences-Announces-DSIMS-Drug-Safety-Information-Management-Suite-132403-1.htm</guid>
</item>
<item>
<title><![CDATA[IDSA Proposes New Pathway For Antibiotic Approval]]></title>
 <link>http://www.medindia.net/health-press-release/IDSA-Proposes-New-Pathway-For-Antibiotic-Approval-132163-1.htm</link>
 <description><![CDATA[
	
	
	"Special Population Limited Medical Use" mechanism provides drug development incentives 
	WASHINGTON, March 8, 2012 /PRNewswire-USNewswire/ -- Congress will consider a new drug approval pathway to encourage development ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/IDSA-Proposes-New-Pathway-For-Antibiotic-Approval-132163-1.htm</guid>
</item>
<item>
<title><![CDATA[Data in NEJM shows Novartis drug Signifor (Regd)  is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study]]></title>
 <link>http://www.medindia.net/health-press-release/Data-in-NEJM-shows-Novartis-drug-Signifor-is-first-therapy-to-provide-rapid-durable-benefit-for-Cushings-disease-patients--132129-1.htm</link>
 <description><![CDATA[-- Study met primary endpoint showing Signifor (pasireotide) normalized cortisol overproduction, a critical factor in controlling the debilitating endocrine disorder(1,2,3)
	tr style="PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: ]]></description>
 <guid isPermaLink="false">http://www.medindia.net/health-press-release/Data-in-NEJM-shows-Novartis-drug-Signifor-is-first-therapy-to-provide-rapid-durable-benefit-for-Cushings-disease-patients--132129-1.htm</guid>
</item>
</channel>
</rss>

